Precision BioSciences und Servier erweitern ihre Zusammenarbeit in der CAR-T-Entwicklung im Bereich Onkologie mit vier neuen Programmen, die auf hämatologische und solide Tumore abzielen
September 17, 2020 15:49 ET
|
Precision Biosciences
DURHAM, N.C. und PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), ein Biotechnologieunternehmen im Bereich der klinischen Forschung, das in Zusammenarbeit mit...
Precision BioSciences et Servier étendent leur collaboration en matière de développement en oncologie concernant un traitement à base de cellules CAR T avec quatre nouveaux programmes ciblant les tumeurs hématologiques et solides
September 17, 2020 15:49 ET
|
Precision Biosciences
DURHAM, Caroline du Nord, et PARIS, 17 sept. 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq : DTIL), une société biotechnologique en phase clinique développant des traitements par...
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
September 17, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C. and PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction...
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
September 09, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September
September 02, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy
August 19, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
August 13, 2020 07:00 ET
|
Precision Biosciences
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma PBCAR0191 and PBCAR20A Clinical Studies Progressing; Updated Interim...
Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences
August 03, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
July 06, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma
June 08, 2020 07:00 ET
|
Precision Biosciences
-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic – -PBCAR269A is the...